Her-1, her-3 and igf-1r compositions and uses thereof
AssigneeOhio State Innovation Foundation
InventorPravin T.P. KAUMAYA
Life of this patent
Estimating the term…
Abstract
Provided herein are HER-3, HER-1 and IGF-1R B cell epitopes, peptide mimics, chimeric peptides and multivalent peptides. In some embodiments, the chimeric peptides include one or more HER-3, HER-1 and/or IGF-1R B cell epitopes, a linker, and a T helper cell (Th cell) epitope. Pharmaceutical compositions are also provided that contain one or more HER-3, HER-1 and/or IGF-1R chimeric peptides, and optionally, one or more HER-2 chimeric peptides and/or VEGF peptides. Also included herein are methods of treating a cancer using the HER-3, HER-1 and IGF-1R B cell epitopes, chimeric peptides and multivalent peptides.
Claims21
A method of treating a cancer comprising administering to a subject with a cancer a HER-3 chimeric peptide for stimulating an immune response to a HER-3 protein comprising one or more HER-3 B cell epitopes, a T helper (Th) epitope, and a linker joining the HER-3 B cell epitope to the Th epitope, wherein
- a. the one or more HER-3 B cell epitopes consist of a sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7;
- b. the Th epitope comprises a sequence selected from the group consisting of:
- SEQ ID NO:
- 12, SEQ ID NO:13, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16 SEQ ID NO:
- 17, SEQ ID NO:
- 18, and SEQ ID NO;
- 19;
- and
- c. the linker comprises a sequence that is from 1 to 15 amino acids in length.
A method of treating a cancer comprising administering to a subject with a cancer a HER-1 chimeric peptide for stimulating an immune response to a HER-1 protein comprising one or more HER-1 B cell epitopes, a T helper (Th) epitope, and a linker joining the HER-1 B cell epitope to the Th epitope, wherein:
- a. the one or more HER-1 B cell epitopes consist of a sequence selected from the group consisting of:
- SEQ ID NO:
- 1, SEQ ID NO:
- 2, and SEQ ID NO:
- 3;
- b. the Th epitope comprises a sequence selected from the group consisting of:
- SEQ ID NO:
- 12, SEQ ID NO:13, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16 SEQ ID NO:
- 17, SEQ ID NO:
- 18, and SEQ ID NO:19;
- and
- c. the linker comprises a sequence that is from 1 to 15 amino acids in length.
A method of treating a cancer comprising administering to a subject with a cancer an IGF-1R chimeric peptide for stimulating an immune response to an IGF-1R protein comprising one or more IGF-1R B cell epitopes, a T helper (Th) epitope, and a linker joining the IGF-1R B cell epitope to the Th epitope, wherein
- a. the one or more IGF-1R B cell epitopes consist of a sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11;
- b. the Th epitope comprises a sequence selected from the group consisting of:
- SEQ ID NO:
- 12, SEQ ID NO:13, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16 SEQ ID NO:
- 17, SEQ ID NO:
- 18, and SEQ ID NO:19;
- and
- c. the linker comprises a sequence that is from 1 to 15 amino acids in length.
Dependencies are inferred from the claim text.